ISEL: A Phase III survival study comparing gefitinib (IRESSA) plus best supportive care (BSC) with placebo plus BSC, in patients with advanced non-small cell lung cancer (NSCLC) who had received one or two prior chemotherapy regimens

Reviewer: James M. Metz, MD
Abramson Cancer Center of the University of Pennsylvania
Ultima Vez Modificado: 6 de julio del 2005

Translation for this article does not exist